Glaukos Corporation (NYSE:GKOS) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Monday.

Several other equities research analysts have also commented on the stock. Stephens reiterated a “buy” rating and issued a $47.00 price objective on shares of Glaukos Corporation in a research report on Friday, September 15th. Piper Jaffray Companies reiterated a “buy” rating and issued a $38.00 price objective on shares of Glaukos Corporation in a research report on Friday, September 15th. Stifel Nicolaus reiterated a “buy” rating on shares of Glaukos Corporation in a research report on Thursday, September 14th. Cantor Fitzgerald reiterated a “buy” rating and issued a $60.00 price objective (up from $54.00) on shares of Glaukos Corporation in a research report on Thursday, September 14th. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $54.00 price objective on shares of Glaukos Corporation in a research report on Friday, September 1st. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $49.86.

Glaukos Corporation (GKOS) opened at 32.53 on Monday. Glaukos Corporation has a 1-year low of $28.72 and a 1-year high of $52.49. The stock’s market capitalization is $1.12 billion. The stock has a 50 day moving average of $36.29 and a 200 day moving average of $36.29.

ILLEGAL ACTIVITY WARNING: “Glaukos Corporation (GKOS) Stock Rating Lowered by BidaskClub” was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://theolympiareport.com/2017/09/20/glaukos-corporation-gkos-stock-rating-lowered-by-bidaskclub.html.

In other Glaukos Corporation news, CEO Thomas William Burns sold 73,788 shares of the company’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $41.36, for a total value of $3,051,871.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Orbimed Advisors Llc sold 580,200 shares of the company’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $38.73, for a total transaction of $22,471,146.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 980,200 shares of company stock worth $37,900,263. 16.40% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in GKOS. Janus Henderson Group PLC purchased a new position in Glaukos Corporation in the 2nd quarter valued at about $129,356,000. Janus Capital Management LLC lifted its holdings in Glaukos Corporation by 88.5% in the 1st quarter. Janus Capital Management LLC now owns 1,765,069 shares of the medical instruments supplier’s stock valued at $90,545,000 after purchasing an additional 828,567 shares in the last quarter. Koch Industries Inc. purchased a new position in Glaukos Corporation in the 2nd quarter valued at about $683,000. Bamco Inc. NY lifted its holdings in Glaukos Corporation by 75.7% in the 2nd quarter. Bamco Inc. NY now owns 1,072,246 shares of the medical instruments supplier’s stock valued at $44,466,000 after purchasing an additional 462,019 shares in the last quarter. Finally, Capital World Investors lifted its holdings in Glaukos Corporation by 17.1% in the 2nd quarter. Capital World Investors now owns 2,740,000 shares of the medical instruments supplier’s stock valued at $113,628,000 after purchasing an additional 400,000 shares in the last quarter.

About Glaukos Corporation

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Analyst Recommendations for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.